Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06986603 · ClinicalTrials.gov registry record · Phase 4
Glucagon Dose-Response in Patients With Post-Bariatric Hypoglycemia
A Phase 4 study of Hypoglycemia and Bariatric Surgery, sponsored by Joslin Diabetes Center.
- Active
- Registry status
- Phase 4
- Development phase
- 28
- Enrollment target
- 2
- Study locations
NCT06986603 is a Phase 4 study of Hypoglycemia and Bariatric Surgery that is active but no longer recruiting, run by Joslin Diabetes Center. The registered enrollment target is 28 participants, below the 506-participant average among 40 other Hypoglycemia trials with a reported enrollment target (94% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT06986603, a Phase 4 study of Hypoglycemia and Bariatric Surgery, is active but no longer recruiting, sponsored by Joslin Diabetes Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 28 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of the study is to determine how blood sugar levels in individuals with and without hypoglycemia after bariatric surgery respond to different doses of glucagon, a hormone that is usually present in your body that regulates blood sugar levels. In this study, there will be 4 visits to the clinical research center. In the first visit, medical history and physical exam will be performed, and blood samples will be taken to assess overall health. During visit 2, a continuous glucose monitor will be placed under the skin. (This may be combined with visit 1, depending on the schedule of visits.) In visit 3, we will test the effect of a total of 4 different doses of glucagon, in increasing doses. In visit 4, we will test the effect of a total of 3 doses of glucagon, in decreasing doses. For both visit 3 and 4, we will infuse labeled stable glucose to allow us to measure how much glucose the body is making, and will measure levels of hormones which regulate glucose, such as insulin and glucagon.
Conditions Studied
Interventions
- DRUG Glucagon for Injection (Fresenius Kabi USA)
Study Locations (2)
Alabama
- University of Alabama - Birmingham
Massachusetts
- Joslin Diabetes Center - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2024-11-26 |
| Est. Completion | 2026-09-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06986603
The ClinicalTrials.gov registry entry for NCT06986603 describes a study currently listed as active not recruiting, categorized as Phase 4. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 506-participant average among 40 other Hypoglycemia trials with a reported enrollment target (94% lower). The listed sponsor is Joslin Diabetes Center, which has 73 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Hypoglycemia appearing as the primary indexed condition, and to 1 intervention - of which Glucagon for Injection (Fresenius Kabi USA) is the first listed.
NCT06986603 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Alabama, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06986603 about?
NCT06986603 is a clinical study titled "Glucagon Dose-Response in Patients With Post-Bariatric Hypoglycemia". The purpose of the study is to determine how blood sugar levels in individuals with and without hypoglycemia after bariatric surgery respond to different doses of glucagon, a hormone that is usually present in your body that regulates blood sugar levels. In this study, there will be 4 visits to the ...
What is the current status of trial NCT06986603?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 28 participants. The study started on 2024-11-26. Estimated completion is 2026-09-01.
What conditions does trial NCT06986603 study?
This clinical trial studies the following conditions: Hypoglycemia, Bariatric Surgery, Hypoglycemia, Reactive.
What interventions are being tested in trial NCT06986603?
The interventions under investigation include: Glucagon for Injection (Fresenius Kabi USA) (DRUG).
Who is sponsoring clinical trial NCT06986603?
This trial is sponsored by Joslin Diabetes Center, which has 73 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06986603 being conducted?
This trial has 2 study locations across Alabama, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypoglycemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
External Carotid Blood Flow in Individuals With Post-Bariatric Hypoglycemia
RECRUITING
-
A Study to Investigate Safety and Effectiveness of Porcine Pancreatic Cells (OPF-310) in Patients With Type 1 Diabetes Mellitus
RECRUITING · Phase 1
-
Diabetes Clinical Decision Support
RECRUITING · NA
-
Effect of Fasting on Hypoglycemic Counterregulation in Type 1 Diabetes
RECRUITING · NA
-
Enhancing Shared Decision-making to Guide Care for People With Dementia and Diabetes
RECRUITING · NA
-
Evaluating Glial Acetate Metabolism as a Biomarker of Hypoglycemic Counterregulation
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.